FDA offers bioequivalance API guidance; U.S. gets BASF's API HQ; Daiichi Sankyo consolidates;

> The FDA has issued draft guidelines for dozen of APIs intended to provide insight for drugmakers designing bioequivalance studies. Guidelines

> BASF ($BASF) will move the world headquarters for its API and excipient operations, Pharma Ingredients & Services, to Florham Park, NJ, from Switzerland. Item

> Japanese drugmaker Daiichi Sankyo is consolidating two plants and its logistics operations to make them more efficient. Item

> Indian drugmaker Anil Bioplus says it will spend about $28 million to build a plant in Halol, India, where it will manufacture enzymes and bio-chemical products. Report

> Lonza will manufacture Mydicar, an enzyme replacement therapy, for trials for developer Celladon, with the potential for a supply agreement if the treatment is approved. Item

And Finally... Indian manufacturer Dishman Pharmaceuticals and Chemicals says it intends to launch 60 generic APIs over the next 24 months. Story